Phio Pharmaceuticals Corp.
PHIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001533040
In the last 90 days, Phio Pharmaceuticals Corp. insiders filed 5 open-market purchases and 0 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $662.6K in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Phio Pharmaceuticals Corp. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 11 | 17 | +6 |
| Shares | 188.5K | 363.8K | +175.4K (+93.0%) |
| Value | $467.4K | $382.3K | −$85.1K (−18.2%) |
New holders (8)
Institutions that held Phio Pharmaceuticals Corp. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Northern Trust Corp | 23,758 | $24.9K | 0.00% |
| DRW Securities, LLC | 22,636 | $23.8K | 0.00% |
| Susquehanna International Group, LLP | 20,091 | $21.1K | 0.00% |
| Two Sigma Investments, LP | 14,494 | $15.2K | 0.00% |
| StoneX Group Inc. | 11,828 | $12.4K | 0.00% |
| Robertson Stephens Wealth Management, LLC | 10,800 | $11.3K | 0.00% |
| Virtu Financial LLC | 10,214 | $11.0K | 0.00% |
| Captrust Financial Advisors | 10,000 | $10.5K | 0.00% |
Sold out (2)
Institutions that held Phio Pharmaceuticals Corp. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| BNP Paribas Arbitrage, SA | 413 | $1.02K |
| Tower Research Capital LLC (TRC) | 406 | $1.01K |